Brief: ZyVersa Therapeutics - Expect To Complete Preclinical Program For IC 100 By Year's End
13/06/2023 14:33
June 13 (Reuters) - ZyVersa Therapeutics Inc ZVSA.O :
* ZYVERSA THERAPEUTICS - EXPECT TO COMPLETE PRECLINICAL
PROGRAM
FOR IC 100 BY YEAR'S END, AND FILE AN IND TO INITIATE A PHASE 1
TRIAL IN EARLY 2024
Source text for Eikon: ID:nGNX8MKk31
Further company coverage: ZVSA.O
(reuters.briefs@thomsonreuters.com)
Recent news on Zyversa Therapeutics
See all newsBrief: ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million
Brief: ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity
Brief: Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation
Brief: ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative Research And Development Trends For Inflammasome Inhibitors, And Provides Update On Inflammasome ASC Inhibitor IC 100’S Development Status
Brief: Zyversa Therapeutics Files For Prospectus Related To Offer & Resale Of Up To 1.6 Million Shares Of Common Stock By Selling Stockholder - SEC Filing